Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Keunchil ParkEric B HauraNatasha B LeighlPaul MitchellCatherine A ShuNicolas GirardSantiago ViteriJi-Youn HanSang-We KimChee Khoon LeeJoshua K SabariAlexander I SpiraTsung-Ying YangDong Wan KimKi Hyeong LeeRachel E SanbornJosé TrigoKoichi GotoJong-Seok LeeJames Chih-Hsin YangRamaswamy GovindanJoshua M BaumlPilar Garrido LopezMatthew G KrebsKaren L ReckampJohn XieJoshua C CurtinNahor Haddish-BerhaneAmy RoshakDawn MillingtonPatricia LorenziniMeena ThayuRoland E KnoblauchByoung Chul ChoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.